UK and US Finalize Groundbreaking Tariff-Free Pharma Trade Deal

The UK has secured a landmark pharmaceutical trade agreement with the U.S., granting tariff-free export of UK medicines in exchange for increased prices on new drugs. This deal fortifies Britain's pharmaceutical foothold in the U.S. market while enhancing cooperation between healthcare regulatory bodies.

In a significant advancement in UK-U.S. trade relations, a new pharmaceutical trade deal provides tariff-free access for British medicines to the American market. In return, the British government has agreed to raise prices on new drugs, promising a 25% price hike for NHS acquisitions starting April 2026.

The agreement, a part of a broader U.S.-UK trade accord, ensures protection for high-skilled jobs and secures Britain's position as a leading pharmaceutical exporter to the U.S., representing a fifth of British exports to the nation by value. As part of the deal, British companies like AstraZeneca and GSK forged 'most favoured nation' pricing agreements to shield themselves from future U.S. tariffs.

Both governments have vowed closer collaboration between their regulatory agencies, aiming to streamline access to medical technologies. This deal underscores the robust economic ties and mutual interest in fostering innovation within the pharmaceutical sector, promising stability and growth in cross-Atlantic trade relations.

(With inputs from agencies.)